These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 23564273)

  • 21. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Cutler AJ; Saylor K; Gasior M; Hamdani M; Ferreira-Cornwell MC; Childress AC
    J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):11-21. PubMed ID: 23410138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder.
    Ermer JC; Adeyi BA; Pucci ML
    CNS Drugs; 2010 Dec; 24(12):1009-25. PubMed ID: 21090837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder.
    Najib J; Didenko E; Meleshkina D; Yusupov K; Maw K; Ramnarain J; Tabassum M
    Curr Med Res Opin; 2020 Oct; 36(10):1717-1735. PubMed ID: 32845786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lisdexamfetamine.
    Blick SK; Keating GM
    Paediatr Drugs; 2007; 9(2):129-35; discussion 136-8. PubMed ID: 17407369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of lisdexamfetamine dimesylate for the treatment of ADHD.
    Childress AC; Sallee FR
    Expert Rev Neurother; 2012 Jan; 12(1):13-26. PubMed ID: 22243042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial.
    Childress AC; Arnold V; Adeyi B; Dirks B; Babcock T; Scheckner B; Lasser R; Lopez FA
    J Atten Disord; 2014 Feb; 18(2):123-32. PubMed ID: 22740112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse events in medication treatment-naïve children with attention-deficit/hyperactivity disorder: results from a small, controlled trial of lisdexamfetamine dimesylate.
    Wigal SB; Wong AA; Jun A; Stehli A; Steinberg-Epstein R; Lerner MA
    J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):149-56. PubMed ID: 22372513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day.
    Brams M; Moon E; Pucci M; López FA
    Curr Med Res Opin; 2010 Aug; 26(8):1809-25. PubMed ID: 20491612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lisdexamfetamine: a prodrug stimulant for ADHD.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2008 Aug; 46(8):19-22. PubMed ID: 18777964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lisdexamfetamine dimesylate: in attention-deficit hyperactivity disorder in adults.
    Weber J; Siddiqui MA
    CNS Drugs; 2009; 23(5):419-25. PubMed ID: 19453202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Wigal T; Brams M; Gasior M; Gao J; Giblin J
    Postgrad Med; 2011 Mar; 123(2):169-76. PubMed ID: 21474905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study.
    Turgay A; Ginsberg L; Sarkis E; Jain R; Adeyi B; Gao J; Dirks B; Babcock T; Scheckner B; Richards C; Lasser R; Findling RL
    J Child Adolesc Psychopharmacol; 2010 Dec; 20(6):503-11. PubMed ID: 21186969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized, double-blind, placebo-controlled, crossover study of the effects of lisdexamfetamine dimesylate and mixed amphetamine salts on cognition throughout the day in adults with attention-deficit/hyperactivity disorder.
    Martin PT; Corcoran M; Zhang P; Katic A
    Clin Drug Investig; 2014 Feb; 34(2):147-57. PubMed ID: 24297663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.
    Dew RE; Kollins SH
    Expert Opin Pharmacother; 2010 Dec; 11(17):2907-13. PubMed ID: 20979573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.
    Setyawan J; Hodgkins P; Guérin A; Gauthier G; Cloutier M; Wu E; Erder MH
    J Med Econ; 2013 Oct; 16(10):1203-15. PubMed ID: 23937642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of stimulant treatment for ADHD on later substance abuse and the potential for medication misuse, abuse, and diversion.
    Faraone SV; Upadhyaya HP
    J Clin Psychiatry; 2007 Nov; 68(11):e28. PubMed ID: 18052554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy.
    Ermer JC; Pennick M; Frick G
    Clin Drug Investig; 2016 May; 36(5):341-56. PubMed ID: 27021968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder.
    Adler LA; Alperin S; Leon T; Faraone SV
    J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):196-199. PubMed ID: 27935735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.